Search Results
Jul 30, 2026, 16:05 ET Castle Biosciences Reports Second Quarter 2026 Results
identifying patients at low and high risk of SLN positivity, supporting more informed SLNB decision-making for patients with cutaneous melanoma (CM). This is the second multicenter study showing that the i31-SLNB result outperforms the MIA nomogram in assessing SLN positivity risk. See the Company's
More news about: Castle Biosciences, Inc.
Jun 25, 2026, 16:30 ET DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
factors, with the MIA nomogram, which estimates SLN positivity risk using clinicopathologic factors alone.The study found that patients undergoing SLNB classified as low risk by the i31-SLNB (less than 5% predicted risk of SLN positivity) had an observed SLN positivity rate of 2.6%, showing concordance
More news about: Castle Biosciences, Inc.
May 06, 2026, 16:05 ET Castle Biosciences Reports First Quarter 2026 Results
evaluating DecisionDx-Melanoma's integrated sentinel lymph node biopsy (i31-SLNB) test result. The study data confirmed that the i31-SLNB accurately predicts SLN positivity and identifies low-risk patients who may safely consider forgoing SLNB while maintaining favorable long-term outcomes. These results expanded
More news about: Castle Biosciences, Inc.
May 05, 2026, 07:00 ET Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month
outputs: a personalized risk of sentinel lymph node (SLN) positivity and a personalized risk of recurrence and/or metastasis. This clinically actionable information is designed to help guide risk-aligned patient management decisions, including SLN biopsy consideration, follow-up intensity, imaging and
More news about: Castle Biosciences, Inc.
Apr 21, 2026, 07:00 ET Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
outputs: a personalized risk of sentinel lymph node (SLN) positivity and a personalized risk of recurrence and/or metastasis. This clinically actionable information is designed to help guide risk-aligned patient management decisions, including SLN biopsy consideration, follow-up intensity, imaging and
More news about: Castle Biosciences, Inc.
Mar 27, 2026, 09:05 ET Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
outputs: a personalized risk of sentinel lymph node (SLN) positivity and a personalized risk of recurrence and/or metastasis. This clinically actionable information is designed to help guide risk-aligned patient management decisions, including SLN biopsy consideration, follow-up intensity, imaging and
More news about: Castle Biosciences, Inc.
Mar 25, 2026, 09:00 ET Merlin CP-GEP™ Demonstrates Superior Predictive Accuracy for Sentinel Lymph Node Metastasis in Early-Stage Melanoma
patients with a risk of sentinel lymph node (SLN) positivity above established NCCN guideline thresholds. Merlin CP-GEP is a gene expression profile test recognized by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as predictive of SLN positivity risk, supported by validation in
More news about: SkylineDx
Mar 05, 2026, 09:00 ET SkylineDx Launches a Guideline-Informed Risk Assessment Initiative to Support SLNB Decision-Making in Early-Stage Melanoma
multi-center blinded trial (MERLIN_001) to assess metastatic potential and SLN positivity risk. In this prospective validation study, patients classified as high risk by Merlin CP-GEP demonstrated approximately a three-fold increased risk of SLN involvement compared to low-risk patients⁵.The NCCN Guidelines
More news about: SkylineDx
Feb 19, 2026, 09:00 ET Merlin CP-GEP Becomes the First and Only Gene Expression Profile (GEP) Test Recommended by NCCN® Cutaneous Melanoma Guidelines to Assess Metastatic Risk
Biopsy.NCCN guidelines highlight that patients identified as Merlin High Risk may have a threefold increased risk of sentinel lymph node (SLN) involvement based on recently published data from the largest prospective, blinded trial for a molecular test in cutaneous melanoma.
More news about: SkylineDx
Feb 11, 2026, 08:29 ET GAPVelocity AI Updates VB6 AI Migrator with Visual Studio 2026 Support and New Solution File Format
business logic. The addition of .slnx support gives development teams the flexibility to work with either the new compact solution format or traditional .sln files, depending on their workflow.VB6 AI Migrator is available at
More news about: Growth Acceleration Partners
Jan 30, 2026, 07:30 ET Solace Nutrition Announces Clinical and Scientific Updates for Encala®, the Original Structured-Lipid Medical Food for Fat Malabsorption
Structured Lipid NutritionStructured Lipid Nutrition (SLN) was founded by Virginia Stallings, MD, to develop and commercialize evidence-based nutritional solutions addressing unmet medical needs across human and veterinary health. SLN preserved the Encala® medical food technology and clinically
More news about: Solace Nutrition
Jan 08, 2026, 03:00 ET Independent Dutch Study Further Validates Merlin CP-GEP Test for Melanoma Prognosis
with newly diagnosed clinical stage I and II melanoma between 2007 and 2015. The Merlin CP-GEP Test was successfully performed in 243 patients with a SLN positivity rate of 21.8%. Findings include:The test successfully identified most patients who later experienced disease
More news about: SkylineDx
Oct 22, 2025, 11:30 ET SkylineDx veröffentlicht bahnbrechende MERLIN_001-Studie in JAMA Surgery, die die Vorhersagekraft des Merlin CP-GEP-Tests bei Melanomen bestätigt
sein kann und mit einer höheren Morbidität verbunden ist, identifizierte der Merlin CP-GEP-Test Hochrisikofälle mit einer SLN-Rate von 26,7 % und Niedrigrisikofälle mit einer SLN-Rate von 4,9 % (fünffacher Risikoanstieg in der Hochrisikogruppe gegenüber der Niedrigrisikogruppe).
More news about: SkylineDx
Oct 22, 2025, 11:30 ET SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma
where SLNB can be technically difficult and can carry higher morbidity, the Merlin CP-GEP test identified High-Risk cases with a 26.7% SLN rate and Low-Risk cases with a 4.9% SLN (five-fold risk increase in the High-Risk vs. the Low-Risk groups). Across all ages and primary sites,
More news about: SkylineDx
Sep 24, 2025, 10:50 ET Mobile Gamma Cameras Market Surges to USD 800 Million by 2033, Propelled by 7.3% CAGR - Verified Market Reports®
dependency, raise first-scan success rates, and support staff-constrained providers. Reimbursement and regulatory momentum: Procedure codes for SLN biopsy and thyroid imaging sustain utilization, while radiation dose-tracking and device-safety standards shape purchasing criteria and vendor roadmaps.
More news about: Verified Market Reports